Freeport-McMoRan Inc vs Viatris Inc — how do they compare? Freeport-McMoRan Inc trades at $69.99 (market cap $96.42B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Freeport-McMoRan Inc is far larger — about 5.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| FCX | VTRS | |
|---|---|---|
Market Cap | $96.42B | $18.69B |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $17.86 |
52-Week Low | $35.34 | $9.49 |
Enterprise Value | $102.70B | $30.80B |
Dividend Yield | 0.87% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
FCX trades at $70.53, up 1.31% today, with a bullish technical signal and strong analyst support. Recent earnings beats and robust cash flow from operations highlight operational strength. The stock is near its consensus price target of $73.85, with copper market tailwinds and growth initiatives like the Grasberg ramp-up providing positive momentum.
The outlook is positive given earnings momentum and favorable copper prices, but risks include commodity price volatility and execution challenges. With a P/E of 33.76, valuation is elevated, yet growth prospects justify investor optimism. Key risks are macroeconomic sensitivity and capital expenditure demands.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Trailing returns across standard periods
Latest headlines on both assets
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →